- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
ARNA
Now That Obesity Is Classified as a ‘Disease’ …
The American Medical Association's decision to classify obesity as a disease will impact physicians, patients, insurers and pharmaceutical companies.
JCPenney Same-Store Sales Sink: 6 Stocks in 60 Seconds
This week's video: JCPenney's same-store sales fell 17% in Q1. Also, find out why Arena Pharmaceuticals and Toyota are both celebrating.
Dow 15000! — Tuesday’s IP Market Recap
The Dow Jones Industrial Average closed above the 15000 mark for the first time ever, and the S&P 500 continued its record-setting rally.
Belviq Is Not the Next Fen-Phen … Probably
Arena Pharmaceuticals' withdrawal of its European application for Belviq has turned the stock into a three-ring circus. Don't panic -- just get the facts straight.
Data Drives the Rally — Tuesday’s IP Market Recap
Investors got a double good-news whammy on the housing and manufacturing fronts, though homebuilders didn't join in the market's broad-based gains.
Late Stock Rally Pares Losses — Tuesday’s IP Market Recap
Continued concerns over Cyprus held stocks down most of the day, though a late rally cut back losses across the board and helped the Dow finish in the black.
Keryx: An Important Biotech Reality Check in 5, 4, 3 …
This stock's tripling in the past month is your prototypical biotech "win." But if you don't lock in your gains now, you don't understand the game.
Biotech Movers: Arena Gets Warned, MAP Gets an Offer
Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals.
Dow Delivers Despite Iffy Earnings — Tuesday’s Market Recap
The Dow Jones powered ahead Tuesday despite some less-than-splendid earnings from Verizon and Johnson & Johnson. Also, Google impressed after hours.
Stocks Dip on Pre-Earnings Jitters — Tuesday’s IP Market Recap
Investors leery of a potentially weak fourth-quarter earnings season bid stocks down lower Tuesday, though Alcoa "officially" started things off right after the bell.
4 Attractive Biopharma Stocks of All Sizes
Biopharma is a high-growth niche in a defensive sector, but you need to balance risk with reward. Here are four hot biopharma stocks of different sizes.
My Brilliant Biotech Move for 2012
An overly helter-skelter year in the world of biotech stocks has been a stark reminder of a basic lesson that isn't followed enough: Keep it simple.
Biotech Movers: Sequenom Soars on Blood Test Success
SONM sees significant gains despite a sub-par earnings report. Plus: Why Array and Vivus took big falls.
10 Hottest Small-Cap Stocks of 2012
These 10 small to midsize businesses have seen returns ranging from 210 to 670% in just nine months. See which sector makes up most of this high-flying crowd.
8 Biotechnology Stocks to Buy Now
This week, 8 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
Travel Stocks Put on Hold — Wednesday’s IP Market Recap
The Dow Jones and S&P 500 both managed to extend their gains streaks to four consecutive days, but Priceline, Orbitz and the rest of the travel sector didn't join in.
